# Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

> **NCT00170742** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 17 (—)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Octreotide, 30 mg i.m. LAR formulation

## Key facts

- **NCT ID:** NCT00170742
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 17 (—)
- **Why stopped:** trial stopped on Sept 24, 2007
- **Last updated:** 2008-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170742, "Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00170742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*